IntelGenx Technologies (IGXT) has released an update.
IntelGenx Technologies reports promising preliminary results from its Phase 2a BUENA study on Montelukast VersaFilm® for treating mild to moderate Alzheimer’s disease, with a higher dose showing significant cognitive improvement. Despite overall mixed results, the 30-mg twice-daily dose of the buccal film demonstrated a notable benefit, prompting further research. The Alzheimer’s market is projected to grow substantially, indicating a strong potential for new therapies like IntelGenx’s repurposed Montelukast.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.